In mice, two drugs proposed for MS damaged myelin

Credibility

Interest

Share:2 min read

Key Takeaway

Two drugs tested together damaged myelin in mice and disrupted cells that make myelin in a lab dish.

What They Found

Young and older mice given dasatinib and quercetin together lost more myelin than mice given an inactive treatment. The researchers did not see brain cell death in the treated mice. In a lab dish, the drugs disrupted rat cells that were developing into cells that make myelin. Those cells made less of a protein needed for myelin and developed less complex shapes, but they did not die. Gene studies suggested the drugs put stress on the cells, which may help explain why they did not work normally.

Who Should Care and Why

This study used mice and rat cells in a lab dish, not people with MS. The researchers were studying drugs proposed as a way to address aging-related changes linked to MS progression. The mice did not have MS. The lab findings may help researchers model how cells that make myelin stop working normally in MS. The results do not show what these drugs would do to myelin in people with MS.

Important Considerations

You should know this was an animal and lab study, with no human participants. The abstract does not say how many mice or rat cells were studied. It does not show whether the same myelin damage would happen in people with MS.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Progression

Article Topics:

agingdemyelinationmyelinoligodedrocytesenescence

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Proceedings of the National Academy of Sciences of the United States of America often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News